Federated Hermes’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-293
| Closed | -$20K | – | 2372 |
|
|
2019
Q3 | $20K | Sell |
293
-3,063
| -91% | -$210K | ﹤0.01% | 1830 |
|
|
2019
Q2 | $195K | Sell |
3,356
-228,815
| -99% | -$13.6M | ﹤0.01% | 1552 |
|
|
2019
Q1 | $16.3M | Sell |
232,171
-43,634
| -16% | -$3.24M | 0.04% | 399 |
|
|
2018
Q4 | $17.8M | Buy |
275,805
+75,884
| +38% | +$5.32M | 0.05% | 335 |
|
|
2018
Q3 | $14M | Buy |
199,921
+198,320
| +12,387% | +$11.6M | 0.03% | 454 |
|
|
2018
Q2 | $81K | Buy |
1,601
+213
| +15% | +$8.45K | ﹤0.01% | 1637 |
|
|
2018
Q1 | $43K | Buy |
1,388
+74
| +6% | +$2.46K | ﹤0.01% | 1671 |
|
|
2017
Q4 | $45K | Sell |
1,314
-35
| -3% | -$1.12K | ﹤0.01% | 1681 |
|
|
2017
Q3 | $43K | Sell |
1,349
-86
| -6% | -$2.71K | ﹤0.01% | 1669 |
|
|
2017
Q2 | $47K | Buy |
1,435
+68
| +5% | +$2.15K | ﹤0.01% | 1676 |
|
|
2017
Q1 | $43K | Sell |
1,367
-214
| -14% | -$6.33K | ﹤0.01% | 1664 |
|
|
2016
Q4 | $46K | Sell |
1,581
-433
| -21% | -$13.2K | ﹤0.01% | 1681 |
|
|
2016
Q3 | $58K | Sell |
2,014
-19
| -0.9% | -$529 | ﹤0.01% | 1619 |
|
|
2016
Q2 | $53K | Buy |
+2,033
| New | +$54K | ﹤0.01% | 1660 |
|
Federated Hermes's GHDX Position: Q4 2019 in Review
Federated Hermes sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 293 shares — an estimated $20K sold.
Federated Hermes first reported a position in GHDX in Q2 2016 and held it in 14 quarters. The position peaked at $17.8M in Q4 2018. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Federated Hermes reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Federated Hermes sold 293 Genomic Health, Inc. shares in Q4 2019, an estimated $20K.
- Federated Hermes first reported a position in Genomic Health, Inc. in Q2 2016 and held it in 14 quarters.
- Federated Hermes's Genomic Health, Inc. position peaked at $17.8M in Q4 2018.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Federated Hermes's 13F filing for Q4 2019, filed 14 Feb 2020.